KLRS — Kalaris Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1754068 ·
Last close
$2.92
Market Cap
$69.51M
52W High
$11.88
52W Low
$2.91
ADV30
59,823
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,386,000 | -11,515,000 | 99,539,000 | 43,173,000 | 41,867,000 |
| Mar 2026 | 0 | — | -11,833,000 | -10,856,000 | 109,805,000 | 34,427,000 | 41,248,000 |
| Dec 2025 | 0 | — | -10,801,000 | -9,998,000 | 121,736,000 | 98,054,000 | 42,922,000 |
| Sep 2025 | 0 | — | -12,741,000 | -11,894,000 | 81,175,000 | 42,387,000 | 39,310,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,510,000
Investing CF
$-35,367,000
Financing CF
$46,045,000
CapEx
$-17,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.23
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-170,855,000
Inventory
—
Receivables
—
ST Investments
$62,788,000
EBIT TTM
$-44,098,000
Pretax Income TTM
$-44,098,000
Interest Exp TTM
$0
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -46,152,000 | -43,438,000 | 121,736,000 | 42,922,000 | 78,814,000 | -38,370,000 |
| Dec 2024 | 0 | -51,732,000 | -69,167,000 | 6,162,000 | 102,778,000 | -96,616,000 | -20,670,000 |
| Dec 2023 | 0 | -13,464,000 | -14,699,000 | 3,333,000 | 48,350,000 | -45,017,000 | -14,132,000 |
| Dec 2022 | 0 | -14,006,000 | -15,485,000 | 3,899,000 | 34,171,000 | -30,272,000 | -9,779,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CSBR | CHAMPIONS ONCOLOGY, INC. | $68.20M | $4.90 | — |
| OKYO | OKYO Pharma Ltd | $72.42M | $1.38 | — |
| BSEM | BioStem Technologies, Inc. | $73.82M | $4.14 | — |
| INKT | MiNK Therapeutics, Inc. | $62.15M | $12.18 | — |
| EXOZ | EXOZYMES INC. | $57.96M | $6.24 | — |
News headlines (Yahoo Finance, 1h cache)
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-31 12:00 · Yahoo
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
2026-07-20 12:00 · Yahoo
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
2026-07-17 11:00 · Yahoo
Kalaris Appoints Laurie Keating to Board of Directors
2026-07-06 20:05 · Yahoo
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
2026-06-23 12:00 · Yahoo
Kalaris to Present at Clinical Trials at the Summit 2026
2026-06-12 12:00 · Yahoo
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 12:00 · Yahoo
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 12:00 · Yahoo
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
2026-07-14 18:07 · Yahoo
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
2026-03-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.